Company: STAA
Filing Date: 2025-09-24
Form Type: DFAN14A
Source: 0001213900-25-091197
Chunk: 12

Company: STAAR SURGICAL CO
Filing Date: 2025-09-24
Form: DFAN14A
Chunk 12
---
" Reasons to Vote Against the Merger Agreement Proposal Broadwood has been a committed investor in, and strong supporter of, STAAR for more than thirty years. We have provided capital to the Company on various occasions and have purchased a substantial number of additional shares as recently as a few months ago. Today, we beneficially own approximately 27.5% of STAAR’s outstanding shares, making us the Company’s largest stockholder by a significant margin. We initially invested in STAAR more than three decades ago, and have added to our position over time, because we strongly believe in the Company’s ability to create substantial long - term value for stockholders. We believe STAAR’s superior and proprietary technology, as well as its global scale, position the Company to take a significant portion of the refractive surgery market, become a highly profitable enterprise and, ultimately, deliver upon its vision to be the first choice for surgeons and patients seeking visual freedom from glasses and contact lenses. We share management’s view that the Company’s near - term challenges with respect to inventory, tariffs, and other issues are transitory, 1 and we regard them as unlikely to materially diminish the long - term value of the business. In fact, we believe that those challenges have already been substantially resolved 2 and that the Company is poised to return to growth and achieve sustained profitability. Furthermore, recent clinical data indicate that the advantages of STAAR’s technology over laser refractive surgery technologies are greater than was previously recognized 3 which, in our view, suggests that the Company’s market share gains are likely to accelerate in the future. In light of STAAR’s promising future, it is puzzling to us that the Board chose this moment to sell the Company — and especially that it chose to do so following a process that we believe was deficient and at a price we regard as inadequate. For these reasons, we oppose the Proposed Merger and are soliciting your proxy to vote “ AGAINST ” the adoption of the Merger Agreement Proposal. A Kcficicnǐ F»occss Competition in the ophthalmic surgical market is intense, as STAAR acknowledges. 4 There are several global, well - capitalized companies that market lasers for corneal refractive surgery 5 (including the LASIK procedure) and many more companies in adjacent or related businesses that we believe would view the Company as a complementary and potentially attractive acquisition target. Yet, despite the existence of a ready pool of — in our view — logical, well - capitalized potential buyers, the Board